NO327878B1 - Faktor X-analoger med modifiserte spaltningsseter for proteaser - Google Patents

Faktor X-analoger med modifiserte spaltningsseter for proteaser Download PDF

Info

Publication number: NO327878B1
Authority: NO; Norway
Prior art keywords: factor; analogue; protease; amino acid; chain
Prior art date: 1997-02-27

Application number

NO19994139A

Other languages

English (en)

Norwegian (no)

Other versions

NO994139L (no

NO994139D0 (no

Inventor

Friedrich Dorner

Johann Eibl

Uwe Schlokat

Michele Himmelspach

Andreas Fisch

Original Assignee

Baxter Innovations Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-27

Filing date

1999-08-26

Publication date

2009-10-12

1999-08-26 Application filed by Baxter Innovations Gmbh filed Critical Baxter Innovations Gmbh

1999-08-26 Publication of NO994139D0 publication Critical patent/NO994139D0/no

1999-10-27 Publication of NO994139L publication Critical patent/NO994139L/no

2009-10-12 Publication of NO327878B1 publication Critical patent/NO327878B1/no

Links

108010014173 Factor X Proteins 0.000 title claims description 321
102000035195 Peptidases Human genes 0.000 title claims description 126
108091005804 Peptidases Proteins 0.000 title claims description 126
239000004365 Protease Substances 0.000 title claims description 125
238000003776 cleavage reaction Methods 0.000 title claims description 91
230000007017 scission Effects 0.000 title claims description 90
108010074860 Factor Xa Proteins 0.000 claims description 161
108090001126 Furin Proteins 0.000 claims description 111
235000019419 proteases Nutrition 0.000 claims description 96
238000002360 preparation method Methods 0.000 claims description 91
102000004961 Furin Human genes 0.000 claims description 74
230000004913 activation Effects 0.000 claims description 72
238000012545 processing Methods 0.000 claims description 69
230000004048 modification Effects 0.000 claims description 58
238000012986 modification Methods 0.000 claims description 58
210000004027 cell Anatomy 0.000 claims description 54
150000001413 amino acids Chemical class 0.000 claims description 46
230000000694 effects Effects 0.000 claims description 46
102100035233 Furin Human genes 0.000 claims description 37
125000003275 alpha amino acid group Chemical group 0.000 claims description 35
238000000034 method Methods 0.000 claims description 34
230000014509 gene expression Effects 0.000 claims description 31
238000000338 in vitro Methods 0.000 claims description 31
101710118538 Protease Proteins 0.000 claims description 26
102000012479 Serine Proteases Human genes 0.000 claims description 26
108010022999 Serine Proteases Proteins 0.000 claims description 26
238000004519 manufacturing process Methods 0.000 claims description 26
108090000623 proteins and genes Proteins 0.000 claims description 22
101800001401 Activation peptide Proteins 0.000 claims description 21
102400000069 Activation peptide Human genes 0.000 claims description 21
238000011534 incubation Methods 0.000 claims description 21
108090000765 processed proteins & peptides Proteins 0.000 claims description 21
102000004169 proteins and genes Human genes 0.000 claims description 20
108060005987 Kallikrein Proteins 0.000 claims description 19
102000001399 Kallikrein Human genes 0.000 claims description 19
101710172072 Kexin Proteins 0.000 claims description 17
239000002243 precursor Substances 0.000 claims description 15
238000001727 in vivo Methods 0.000 claims description 13
239000000543 intermediate Substances 0.000 claims description 13
108010054218 Factor VIII Proteins 0.000 claims description 12
102000001690 Factor VIII Human genes 0.000 claims description 12
229960000301 factor viii Drugs 0.000 claims description 12
210000004899 c-terminal region Anatomy 0.000 claims description 11
230000037430 deletion Effects 0.000 claims description 9
238000012217 deletion Methods 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
238000004587 chromatography analysis Methods 0.000 claims description 8
108020004707 nucleic acids Proteins 0.000 claims description 8
102000039446 nucleic acids Human genes 0.000 claims description 8
150000007523 nucleic acids Chemical class 0.000 claims description 8
108020004511 Recombinant DNA Proteins 0.000 claims description 6
108020005038 Terminator Codon Proteins 0.000 claims description 6
230000000468 autoproteolytic effect Effects 0.000 claims description 6
238000003259 recombinant expression Methods 0.000 claims description 6
108010029144 Factor IIa Proteins 0.000 claims description 5
230000035772 mutation Effects 0.000 claims description 5
239000013598 vector Substances 0.000 claims description 5
229960000182 blood factors Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 4
238000000746 purification Methods 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000002797 proteolythic effect Effects 0.000 claims description 3
238000002955 isolation Methods 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims 1
230000009466 transformation Effects 0.000 claims 1
229940012426 factor x Drugs 0.000 description 251
229940024606 amino acid Drugs 0.000 description 44
108091034117 Oligonucleotide Proteins 0.000 description 41
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 37
238000004113 cell culture Methods 0.000 description 30
239000012634 fragment Substances 0.000 description 25
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 24
238000003752 polymerase chain reaction Methods 0.000 description 24
210000004978 chinese hamster ovary cell Anatomy 0.000 description 21
239000012228 culture supernatant Substances 0.000 description 20
239000000047 product Substances 0.000 description 20
239000000203 mixture Substances 0.000 description 19
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 17
230000002950 deficient Effects 0.000 description 17
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 16
238000001262 western blot Methods 0.000 description 16
239000006228 supernatant Substances 0.000 description 15
235000018102 proteins Nutrition 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000013613 expression plasmid Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
230000023555 blood coagulation Effects 0.000 description 9
208000009292 Hemophilia A Diseases 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
208000031220 Hemophilia Diseases 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
108010048049 Factor IXa Proteins 0.000 description 6
108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
102100022641 Coagulation factor IX Human genes 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
101001030665 Dictyostelium discoideum GDP-L-fucose synthase Proteins 0.000 description 5
108010062466 Enzyme Precursors Proteins 0.000 description 5
102000010911 Enzyme Precursors Human genes 0.000 description 5
108010076282 Factor IX Proteins 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
108090000190 Thrombin Proteins 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
229960004222 factor ix Drugs 0.000 description 5
108010014806 prothrombinase complex Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229960004072 thrombin Drugs 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
102100023804 Coagulation factor VII Human genes 0.000 description 4
108010023321 Factor VII Proteins 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108010094028 Prothrombin Proteins 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
235000011148 calcium chloride Nutrition 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
229940012413 factor vii Drugs 0.000 description 4
239000000463 material Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000000758 substrate Substances 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
101100383370 Squalus acanthias CFTR gene Proteins 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108090001015 cancer procoagulant Proteins 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
239000000376 reactant Substances 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
101800005309 Carboxy-terminal peptide Proteins 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108010014172 Factor V Proteins 0.000 description 2
108010061932 Factor VIIIa Proteins 0.000 description 2
108010074864 Factor XI Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
108010000499 Thromboplastin Proteins 0.000 description 2
102000002262 Thromboplastin Human genes 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
229930003448 Vitamin K Natural products 0.000 description 2
239000012190 activator Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000005844 autocatalytic reaction Methods 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000012411 cloning technique Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
-1 except RW Proteins 0.000 description 2
230000006624 extrinsic pathway Effects 0.000 description 2
229940012414 factor viia Drugs 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000006623 intrinsic pathway Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
235000019168 vitamin K Nutrition 0.000 description 2
239000011712 vitamin K Substances 0.000 description 2
150000003721 vitamin K derivatives Chemical class 0.000 description 2
229940046010 vitamin k Drugs 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
101710112984 20 kDa protein Proteins 0.000 description 1
101710091601 21 kDa protein Proteins 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
101800003158 5 kDa peptide Proteins 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
241000024188 Andala Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
241000271032 Daboia russelii Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
206010016077 Factor IX deficiency Diseases 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
108010080865 Factor XII Proteins 0.000 description 1
102000000429 Factor XII Human genes 0.000 description 1
201000007176 Factor XII Deficiency Diseases 0.000 description 1
201000007371 Factor XIII Deficiency Diseases 0.000 description 1
108010071241 Factor XIIa Proteins 0.000 description 1
108010080805 Factor XIa Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241001123589 Gorilla papillomavirus Species 0.000 description 1
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101710159910 Movement protein Proteins 0.000 description 1
101100194604 Mus musculus Rfxap gene Proteins 0.000 description 1
101100537555 Mus musculus Tnfrsf9 gene Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000002085 Prothrombin/thrombin Human genes 0.000 description 1
108050009405 Prothrombin/thrombin Proteins 0.000 description 1
101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108090000787 Subtilisin Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108091005605 Vitamin K-dependent proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical class O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
INJRKJPEYSAMPD-UHFFFAOYSA-N aluminum;silicic acid;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O INJRKJPEYSAMPD-UHFFFAOYSA-N 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000011143 downstream manufacturing Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000007219 factor XI deficiency Diseases 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
208000009429 hemophilia B Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
229940029329 intrinsic factor Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
SBUYBNIDQXQZSZ-UHFFFAOYSA-N p-aminophenylphosphocholine Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC1=CC=C(N)C=C1 SBUYBNIDQXQZSZ-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
229940024790 prothrombin complex concentrate Drugs 0.000 description 1
239000013014 purified material Substances 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000002821 viper venom Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO19994139A 1997-02-27 1999-08-26 Faktor X-analoger med modifiserte spaltningsseter for proteaser NO327878B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0033597A AT405516B (de)	1997-02-27	1997-02-27	Faktor x-analoge mit modifizierter proteasespaltstelle
PCT/AT1998/000045 WO1998038317A1 (de)	1997-02-27	1998-02-27	Faktor x-analoge mit modifizierter proteasespaltstelle

Publications (3)

Publication Number	Publication Date
NO994139D0 NO994139D0 (no)	1999-08-26
NO994139L NO994139L (no)	1999-10-27
NO327878B1 true NO327878B1 (no)	2009-10-12

Family

ID=3487868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994139A NO327878B1 (no)	1997-02-27	1999-08-26	Faktor X-analoger med modifiserte spaltningsseter for proteaser

Country Status (17)

Country	Link
US (2)	US6573071B1 (ja)
EP (1)	EP0966536B1 (ja)
JP (1)	JP4317976B2 (ja)
AR (1)	AR012034A1 (ja)
AT (2)	AT405516B (ja)
AU (1)	AU744428B2 (ja)
BR (1)	BR9807627A (ja)
CA (1)	CA2282707A1 (ja)
CZ (1)	CZ298298B6 (ja)
DE (1)	DE59813518D1 (ja)
ES (1)	ES2263199T3 (ja)
HU (1)	HU225246B1 (ja)
IL (2)	IL131346A0 (ja)
NO (1)	NO327878B1 (ja)
PL (1)	PL190734B1 (ja)
SK (1)	SK286359B6 (ja)
WO (1)	WO1998038317A1 (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT405517B (de) *	1997-02-27	1999-09-27	Immuno Ag	Faktor x-deletionsmutanten und analoge davon
IL129427A0 (en)	1999-04-13	2000-02-17	Yeda Res & Dev	Preparation of biologically active molecules
AT410216B (de) *	1999-08-10	2003-03-25	Baxter Ag	Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) *	2000-03-22	2004-05-27	High Katherine A.	Modified blood clotting factors and methods of use
US7223577B2 (en) *	2000-11-17	2007-05-29	Allergan, Inc.	Post-translational modifications and Clostridial neurotoxins
FR2831170B1 (fr) *	2001-10-19	2004-03-19	Inst Nat Sante Rech Med	Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) *	2002-07-03	2004-08-20	Inst Nat Sante Rech Med	Analogues de facteurs x clivables par la thrombine
US20040132156A1 (en) *	2002-10-04	2004-07-08	Schering Aktiengesellschaft	Modified hepsin molecules having a substitute activation sequence and uses thereof
BRPI0514396A2 (pt) *	2004-08-17	2009-05-12	Csl Behring Gmbh	polipeptìdeos dependentes de vitamina k modificada
EP1728798A1 (en) *	2005-06-01	2006-12-06	ZLB Behring GmbH	Coagulation factor X polypeptides with modified activation properties
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
MX2008006313A (es) *	2005-11-15	2008-11-06	Philadelphia Children Hospital	Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en)	2006-02-21	2007-08-22	CSL Behring GmbH	Coagulation factor X polypeptides with modified activation properties
CA2649800C (en)	2006-04-20	2016-09-20	Kringle Pharma Inc.	Hgf precursor protein variant and active protein thereof
US9956272B2 (en)	2007-05-30	2018-05-01	Bio Products Laboratory Limited	Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) *	2007-05-30	2007-07-11	Nhs Blood & Transplant	Method
US8933197B2 (en) *	2007-08-15	2015-01-13	Amunix Operating Inc.	Compositions comprising modified biologically active polypeptides
CN101802188B (zh)	2007-09-28	2013-08-21	普托拉制药有限公司	用于因子Xa抑制剂的解毒剂和其使用方法
EP2364165B1 (en)	2008-11-14	2018-01-03	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
WO2010091122A1 (en)	2009-02-03	2010-08-12	Amunix, Inc.	Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP2414517B1 (en)	2009-03-30	2016-09-21	Portola Pharmaceuticals, Inc.	Antidotes for factor xa inhibitors and methods of using the same
AU2010258898B8 (en)	2009-06-08	2015-02-05	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
WO2011008885A1 (en)	2009-07-15	2011-01-20	Portola Pharmaceuticals, Inc.	Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
US20120263701A1 (en) *	2009-08-24	2012-10-18	Volker Schellenberger	Coagulation factor vii compositions and methods of making and using same
WO2011123830A2 (en)	2010-04-02	2011-10-06	Amunix Operating Inc.	Alpha 1-antitrypsin compositions and methods of making and using same
US9371522B2 (en)	2011-09-30	2016-06-21	The Children's Hospital Of Philadelphia	Compositions and methods for modulating hemostasis
LT2814840T (lt)	2012-02-15	2020-02-25	Bioverativ Therapeutics Inc.	Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
EP2822577B1 (en)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
WO2013130683A2 (en)	2012-02-27	2013-09-06	Amunix Operating Inc.	Xten conjugate compositions and methods of making same
GB201211617D0 (en)	2012-06-29	2012-08-15	Univ Aberdeen	Production of cyclic peptides
US9145552B2 (en)	2012-07-25	2015-09-29	Catalyst Biosciences, Inc.	Modified factor X polypeptides and uses thereof
MX2015008813A (es)	2013-01-31	2016-03-31	Pfizer	Composiciones y metodos para contrarrestar la inhibicion del factor xa.
FR3001729B1 (fr) *	2013-02-04	2015-03-06	Lab Francais Du Fractionnement	Mutants du facteur x
US20160024487A1 (en) *	2013-03-12	2016-01-28	Novo Nordisk A/S	Thrombin sensitive coagulation factor x molecules
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
MX2016003871A (es)	2013-09-24	2016-08-04	Pfizer	Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.
RU2585532C2 (ru) *	2014-01-31	2016-05-27	Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН)	Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора
US10676731B2 (en)	2014-08-19	2020-06-09	The Children's Hospital Of Philadelphia	Compositions and methods for modulating factor IX function
AU2016301303B2 (en)	2015-08-03	2021-10-07	Bioverativ Therapeutics Inc.	Factor IX fusion proteins and methods of making and using same
EP4129327A1 (en)	2015-08-28	2023-02-08	Amunix Pharmaceuticals, Inc.	Chimeric polypeptide assembly and methods of making and using the same
AU2019270184A1 (en)	2018-05-18	2020-11-26	Bioverativ Therapeutics Inc.	Methods of treating hemophilia A
KR102613936B1 (ko) *	2020-11-13	2023-12-15	한국생명공학연구원	자가분해능이 저하된 켁신 효소 및 이의 생산 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT366916B (de) *	1980-04-02	1982-05-25	Immuno Ag	Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen
US4501731A (en)	1983-06-27	1985-02-26	Tishkoff Garson H	Treatment of disparate bleeding disorders with factor X zymogen
AT382783B (de) *	1985-06-20	1987-04-10	Immuno Ag	Vorrichtung zur applikation eines gewebeklebstoffes
US5597799A (en) *	1990-09-04	1997-01-28	Cor Therapeutics, Inc.	Recombinant agents affecting thrombosis
ATE158816T1 (de)	1990-11-26	1997-10-15	Genetics Inst	Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5621039A (en)	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DE4325872C1 (de)	1993-08-02	1994-08-04	Immuno Ag	Virusinaktivierte Faktor Xa-Präparation
AT401270B (de)	1994-09-26	1996-07-25	Immuno Ag	Verfahren zur quantifizierung von genomischer dna
AT404838B (de)	1995-11-24	1999-03-25	Immuno Ag	Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
AT405517B (de) *	1997-02-27	1999-09-27	Immuno Ag	Faktor x-deletionsmutanten und analoge davon

1997
- 1997-02-27 AT AT0033597A patent/AT405516B/de not_active IP Right Cessation
1998
- 1998-02-25 AR ARP980100832A patent/AR012034A1/es not_active Application Discontinuation
- 1998-02-27 AT AT98903943T patent/ATE324454T1/de active
- 1998-02-27 BR BR9807627-2A patent/BR9807627A/pt not_active IP Right Cessation
- 1998-02-27 HU HU0100652A patent/HU225246B1/hu not_active IP Right Cessation
- 1998-02-27 PL PL98335382A patent/PL190734B1/pl not_active IP Right Cessation
- 1998-02-27 WO PCT/AT1998/000045 patent/WO1998038317A1/de active IP Right Grant
- 1998-02-27 JP JP53706298A patent/JP4317976B2/ja not_active Expired - Lifetime
- 1998-02-27 US US09/367,791 patent/US6573071B1/en not_active Expired - Lifetime
- 1998-02-27 AU AU62002/98A patent/AU744428B2/en not_active Ceased
- 1998-02-27 CZ CZ0303299A patent/CZ298298B6/cs not_active IP Right Cessation
- 1998-02-27 IL IL13134698A patent/IL131346A0/xx active IP Right Grant
- 1998-02-27 SK SK1171-99A patent/SK286359B6/sk not_active IP Right Cessation
- 1998-02-27 DE DE59813518T patent/DE59813518D1/de not_active Expired - Lifetime
- 1998-02-27 EP EP98903943A patent/EP0966536B1/de not_active Expired - Lifetime
- 1998-02-27 CA CA002282707A patent/CA2282707A1/en not_active Abandoned
- 1998-02-27 ES ES98903943T patent/ES2263199T3/es not_active Expired - Lifetime
1999
- 1999-08-10 IL IL131346A patent/IL131346A/en not_active IP Right Cessation
- 1999-08-26 NO NO19994139A patent/NO327878B1/no not_active IP Right Cessation
2003
- 2003-04-04 US US10/407,123 patent/US7220569B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO994139L (no)	1999-10-27
HUP0100652A3 (en)	2003-01-28
AT405516B (de)	1999-09-27
WO1998038317A1 (de)	1998-09-03
PL335382A1 (en)	2000-04-25
US7220569B2 (en)	2007-05-22
US20030181381A1 (en)	2003-09-25
IL131346A0 (en)	2001-01-28
AU744428B2 (en)	2002-02-21
SK286359B6 (sk)	2008-08-05
AR012034A1 (es)	2000-09-27
NO994139D0 (no)	1999-08-26
AU6200298A (en)	1998-09-18
ES2263199T3 (es)	2006-12-01
BR9807627A (pt)	2000-02-22
JP2001513631A (ja)	2001-09-04
SK117199A3 (en)	2000-05-16
CZ303299A3 (cs)	2000-02-16
IL131346A (en)	2007-05-15
JP4317976B2 (ja)	2009-08-19
HUP0100652A1 (hu)	2001-06-28
ATE324454T1 (de)	2006-05-15
EP0966536B1 (de)	2006-04-26
PL190734B1 (pl)	2005-12-30
HU225246B1 (en)	2006-08-28
DE59813518D1 (de)	2006-06-01
CA2282707A1 (en)	1998-09-03
ATA33597A (de)	1999-01-15
CZ298298B6 (cs)	2007-08-22
EP0966536A1 (de)	1999-12-29
US6573071B1 (en)	2003-06-03

Legal Events

Date	Code	Title	Description
2010-09-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO327878B1 (no)	2009-10-12	Faktor X-analoger med modifiserte spaltningsseter for proteaser
NO328022B1 (no)	2009-11-09	Faktor XΔ-analog, rekombinant DNA som koder for denne, celler inneholdende slikt DNA samt preparat, anvendelse av preparatet og fremgangsmate for fremstilling av slike preparater inneholdende XΔ-analogene
US9249404B2 (en)	2016-02-02	Coagulation factor X polypeptides with modified activation properties
US6958322B1 (en)	2005-10-25	Factor X analog with an improved ability to be activated
MXPA99007817A (en)	2001-05-17	Factor x deletion mutants and analogues thereof
MXPA99007768A (en)	2000-08-01	Factor x analogues with a modified protease cleavage site